Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $9.7 million.

  • Verrica Pharmaceuticals' Free Cash Flow rose 21295.78% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.1 million, marking a year-over-year increase of 5119.42%. This contributed to the annual value of -$61.0 million for FY2024, which is 5653.71% down from last year.
  • Verrica Pharmaceuticals' Free Cash Flow amounted to $9.7 million in Q3 2025, which was up 21295.78% from -$10.0 million recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Free Cash Flow registered a high of $9.7 million during Q3 2025, and its lowest value of -$19.9 million during Q1 2024.
  • Moreover, its 5-year median value for Free Cash Flow was -$8.9 million (2021), whereas its average is -$8.4 million.
  • In the last 5 years, Verrica Pharmaceuticals' Free Cash Flow crashed by 95102.97% in 2023 and then soared by 21295.78% in 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' Free Cash Flow (Quarter) stood at -$8.9 million in 2021, then soared by 43.82% to -$5.0 million in 2022, then plummeted by 193.51% to -$14.7 million in 2023, then dropped by 9.03% to -$16.1 million in 2024, then soared by 160.29% to $9.7 million in 2025.
  • Its Free Cash Flow stands at $9.7 million for Q3 2025, versus -$10.0 million for Q2 2025 and -$12.7 million for Q1 2025.